



PRODUCT: **Polivy™**

COMPANY:

Genentech, a member of the Roche Group.

THERAPEUTIC AREA & INDICATION:

Antibody drug conjugate for treatment
of diffuse large B-cell lymphoma

ABOUT THE PRODUCT

POLIVY is a first-in-class CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies. The randomized controlled Phase II trial of Polivy plus bendamustine and Rituxan (BR) is the first and only randomized study to show overall survival benefit in this patient population with high unmet medical need. With a predictable safety profile, Polivy represents a readily available, much-needed treatment option for people with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).